Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Matthew R. Sydes"'
Autor:
Noel W. Clarke, Claire Amos, Hassan Douis, Nicholas D. James, Gerhardt Attard, Malcolm David Mason, Mahesh K. B. Parmar, Adrian Cook, Chris Parker, Alex Hoyle, J. Calvert, Christopher D. Brawley, Adnan Ali, Matthew R. Sydes
Publikováno v:
Ali, A, Hoyle, A, Parker, C C, Brawley, C D, Cook, A, Amos, C, Calvert, J, Douis, H, Mason, M D, Attard, G, Parmar, M K B, Sydes, M R, James, N D & Clarke, N 2020, ' The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer : An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison” ', European Urology Oncology . https://doi.org/10.1016/j.euo.2020.05.003
European Urology Oncology
European Urology Oncology
Background Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden metastatic prostate cancer. The current criterion to define this clinical state is based on manual bone metastasis counts, but enumeration of bone me
Autor:
Malcolm David Mason, Robin Millman, Alison Birtle, Duncan McLaren, David Matheson, Stephanie Gibbs, John Graham, Prabir Chakraborti, Mahesh K. B. Parmar, Joanna Gale, Matthew S. Simms, Melissa Gannon, John Wagstaff, Anna T.H. Tran, J. Martin Russell, Robert Hughes, Joe M. O'Sullivan, Santhanam Sundar, Omi Parikh, Beth Woods, Mymoona Alzouebi, Audrey Cook, Richard Cathomas, Angus Robinson, Eleftherios Sideris, Robert Jones, Robert W. Laing, Susannah Brock, Clive Peedell, Narayanan Srihari, Chris Parker, Shaun Tolan, Gerhardt Attard, Nicholas D. James, Matthew R. Sydes, Alastair W. S. Ritchie, Andrew Protheroe, Mark Sculpher, William Cross, David Tsang, George N. Thalmann, Rajaguru Srinivasan, John Staffurth, David P. Dearnaley
Publikováno v:
Woods, B S, Sideris, E, Sydes, M R, Gannon, M R, Parmar, M K B, Alzouebi, M, Attard, G, Birtle, A J, Brock, S, Cathomas, R, Chakraborti, P R, Cook, A, Cross, W R, Dearnaley, D P, Gale, J, Gibbs, S, Graham, J D, Hughes, R, Jones, R J, Laing, R, Mason, M D, Matheson, D, McLaren, D B, Millman, R, O'Sullivan, J M, Parikh, O, Parker, C C, Peedell, C, Protheroe, A, Ritchie, A W S, Robinson, A, Russell, J M, Simms, M S, Srihari, N N, Srinivasan, R, Staffurth, J N, Sundar, S, Thalmann, G N, Tolan, S, Tran, A T H, Tsang, D, Wagstaff, J, James, N D & Sculpher, M J 2018, ' Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness ', European urology oncology, vol. 1, no. 6, pp. 449-458 . https://doi.org/10.1016/j.euo.2018.06.004
European Urology Oncology
European Urology Oncology
Background Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs fai
Autor:
Chee Goh, Peter Cooke, Anjali Zarkar, Holly Pickering, Noel W. Clarke, Julian Money-Kyrle, Henriette Lindberg, Wendy R. Parulekar, Klaus Brasso, Mahesh K. B. Parmar, Martin Andreas Røder, Jason F. Lester, S L Morris, Nicholas D. James, Amit Bahl, Rajendra Persad, William Cross, Stephanie Gibbs, Charles Catton, Henrik Jakobsen, Peter Ostler, Rakesh Raman, James M. Wilson, Ian Sayers, Matthew R. Sydes, Ramasamy Jaganathan, Heather Payne, Lisa Owen, Howard Kynaston, Joe M. O'Sullivan, Adrian Cook, Sandeep Gujral, Alvan Pope, Ben Eddy, Chris Parker, Matthew S. Simms, Juliette Anderson, Rick Popert, Prashant Patel, Alastair Henderson, David Bottomley, John P Logue, Peter Meidahl Petersen, Fred Saad, Kathryn Lees, Rohit Chahal, Catherine Heath, S.K. Sundaram
Publikováno v:
Lancet (London, England). 396(10260)
Summary Background The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy with salvage radiotherapy for prosta
Autor:
Carlos Diaz-Montana, Archie Macnair, Barbara E. Bierer, Annabelle South, Katie Gillies, Matthew R. Sydes, Talia Isaacs, William J. Cragg, Nalinie Joharatnam-Hogan, Andrew Copas, Cara Purvis, Claire Snowdon, Elizabeth C. James, Conor D. Tweed
Publikováno v:
PLoS Medicine, Vol 18, Iss 10, p e1003798 (2021)
PLoS Medicine
PLoS Medicine
Background Sharing trial results with participants is an ethical imperative but often does not happen. We tested an Enhanced Webpage versus a Basic Webpage, Mailed Printed Summary versus no Mailed Printed Summary, and Email List Invitation versus no
Autor:
Janet E. Brown, J.M. Russell, Hassan Douis, Adrian Cook, Matthew R. Sydes, David Matheson, Narayanan Srihari, Alex Hoyle, Matthew S. Simms, A. Nikapota, Anjali Zarkar, Christopher D. Brawley, F.C. Ingleby, Noel W. Clarke, J. Calvert, John Wagstaff, Duncan C. Gilbert, Gerhardt Attard, Jacob Tanguay, A.W.S. Ritchie, Adnan Ali, Ruth E Langley, Andrew Protheroe, Aurelius Omlin, H. Rush, Anna Lydon, David P. Dearnaley, Malcolm David Mason, James D. Wylie, Silke Gillessen, Simon Chowdhury, L. Capaldi, Sharon Beesley, Joe M O'Sullivan, Mona Parmar, Omi Parikh, Joanna Gale, Jan Wallace, S. Rudman, Chris Parker, Alison Birtle, Archie Macnair, Claire Amos, Stephanie Gibbs, Robin Millman, Robert Jones, Zafar Malik, William Cross, Nicholas D. James, Shaun Tolan
Publikováno v:
STAMPEDE Investigators 2019, ' Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial ', Annals of Oncology . https://doi.org/10.1093/annonc/mdz396
Annals of Oncology
Annals of Oncology
Background\ud \ud STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae50219cab2735395675e6bd870c6e64
https://doi.org/10.1093/annonc/mdz396
https://doi.org/10.1093/annonc/mdz396
Autor:
Christina Wong, Karen Gibbon, C. Green, Daniel J. Bratton, Margaret E. Cruickshank, Hazel Bell, Matthew R. Sydes, Kim S Thomas, R.C. Simpson, Helen Nankervis, Shaheen Haque, Ruth Murphy, Kate London, Shelley Dowey, C. M. Owen, Sally R. Wilkes
Publikováno v:
Journal of lower genital tract disease. 22(4)
Autor:
Antoine, Kass-Iliyya, Gordana, Jovic, Claire, Murphy, Cyril, Fisher, Isabel, Syndikus, Chakiath, Jose, Christopher D, Scrase, John D, Graham, David, Nicol, Matthew R, Sydes, David, Dearnaley
Publikováno v:
European Urology
Background The importance of 2-yr postradiotherapy prostate biopsy status remains uncertain. Objective To assess the value of 2 year post treatment biopsies in a randomised trial of radiotherapy dose escalation. Design, setting, and participants Betw
Autor:
Michael Brundage, Charles Hayter, J. Hetherington, Jinka Sathya, Malcolm David Mason, John Anderson, Jim Barber, Mary Gospodarowicz, Salah El-Sharkawi, Michael McKenzie, Padraig Warde, Matthew R. Sydes, P.D. John Hardman, Luis Souhami, Peter Kirkbride, Edmund C. Kostashuk, Richard A Cowan, Gregory P. Swanson, Mahesh K. B. Parmar, Gordana Jovic, Wendy R. Parulekar, Andrea Hiltz, Bingshu E. Chen
Publikováno v:
Journal of Clinical Oncology
Purpose We have previously reported that radiotherapy (RT) added to androgen-deprivation therapy (ADT) improves survival in men with locally advanced prostate cancer. Here, we report the prespecified final analysis of this randomized trial. Patients
Autor:
Joanna Gale, C.L. Ferguson, J. Martin Russell, Prabir Chakraborti, Carys Thomas, Mohan Hingorani, Joe M. O'Sullivan, Anjali Zarkar, Clare Gilson, Zafar Malik, John Wagstaff, Jo Bowen, Fiona McKinna, Angus Robinson, Claire Amos, Simon Chowdhury, Alison Birtle, Fawzi Adab, Peter Hoskin, San Aung, Robin Millman, Chris Parker, Neil McPhail, Alastair W. S. Ritchie, Robert Jones, Jason F. Lester, Noel W. Clarke, Susannah Brock, Gerhardt Attard, Andrew Protheroe, James D. Wylie, Omi Parikh, Johann S. de Bono, Nicholas D. James, Julian Money-Kyrle, Malcolm David Mason, William Cross, Emma Gray, David Matheson, Dominik Berthold, Silke Gillessen, Melissa R. Spears, David P. Dearnaley, Narayanan Srihari, Matthew R. Sydes, Mahesh K.B. Parmar, Chris Brawley
Publikováno v:
STAMPEDE investigators 2017, ' Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy ', New England Journal of Medicine, vol. 377, no. 4, pp. 338-351 . https://doi.org/10.1056/NEJMoa1702900
STAMPEDE Investigators & Gillessen, S 2017, ' Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy ', The New England Journal of Medicine, vol. 377, no. 4, pp. 338-351 . https://doi.org/10.1056/NEJMoa1702900
The New England journal of medicine, vol. 377, no. 4, pp. 338-351
STAMPEDE Investigators & Gillessen, S 2017, ' Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy ', The New England Journal of Medicine, vol. 377, no. 4, pp. 338-351 . https://doi.org/10.1056/NEJMoa1702900
The New England journal of medicine, vol. 377, no. 4, pp. 338-351
BACKGROUND: Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae654176b4379045bb5aaa6609f18434
https://pure.qub.ac.uk/en/publications/bca063cc-7a5e-46eb-95d8-7e27f2cf88b6
https://pure.qub.ac.uk/en/publications/bca063cc-7a5e-46eb-95d8-7e27f2cf88b6
Autor:
Angela M. Crook, J. Sandercock, Bernard Rachet, E Gordon, Michel P Coleman, Mona Parmar, Chris Williams, Ann Marie Swart, Matthew R. Sydes, John Butler, Manar E. Abdel-Rahman, Peter Harper
Publikováno v:
British Journal of Cancer
Background: Ovarian cancer is the leading cause of death among cancers of the female genital tract, with poor outcomes despite chemotherapy. There was a persistent socioeconomic gradient in 1-year survival in England and Wales for more than 3 decades